10-Q: InMed Pharmaceuticals Reports Q1 2025 Results, Navigates Nasdaq Compliance

InMed Pharmaceuticals reported its financial results for the quarter ended September 30, 2024, while also addressing its Nasdaq listing compliance through a reverse stock split.

Summary

• InMed Pharmaceuticals reported a net loss of $1.7 million for the quarter ended September 30, 2024, compared to a net loss of $2.5 million for the same period in 2023.
• The company's revenue increased to $1.26 million, up from $901,862 in the prior year, primarily driven by sales in the BayMedica Commercial segment.
• Research and development expenses decreased to $771,180 from $1,292,093 year-over-year, mainly due to reduced costs in the INM-755 program.
• General and administrative expenses increased to $1.42 million from $1.3 million year-over-year.
• The company's cash and cash equivalents stood at $5.6 million as of September 30, 2024.
• InMed implemented a 20-for-1 reverse stock split on November 14, 2024, to regain compliance with Nasdaq's minimum bid price requirement.
• The company expects its current cash reserves to fund operations through the end of the first quarter of calendar 2025.
• The company has raised $1.0 million through a private placement and $365,473 through an at-the-market offering during and after the quarter.
• The company has a going concern warning and is dependent on raising additional capital to finance its operations.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the ongoing losses, the going concern warning, and the need for additional capital. However, there are some positive aspects such as revenue growth and cost management efforts.

Positives

• Revenue increased by 40% year-over-year, indicating growth in the BayMedica Commercial segment.
• The net loss decreased compared to the same quarter last year, suggesting improved financial performance.
• Research and development expenses decreased, which may indicate improved cost management.
• The company successfully raised additional capital through a private placement and at-the-market offering.
• The company has taken action to address Nasdaq compliance through a reverse stock split.

Negatives

• The company continues to operate at a loss, with a net loss of $1.7 million for the quarter.
• The company has a going concern warning, indicating substantial doubt about its ability to continue as a going concern.
• The company is dependent on raising additional capital to finance its operations.
• The company's general and administrative expenses increased by 16% year-over-year.

Risks

• The company's ability to continue as a going concern is uncertain, as it is dependent on raising additional capital.
• There is a risk that the reverse stock split may not be successful in maintaining compliance with Nasdaq's minimum bid price requirement.
• Delisting from Nasdaq could have a material and adverse effect on the company's ability to raise capital and the liquidity of its securities.
• The company faces risks related to the development and commercialization of its pharmaceutical products.
• The company is subject to risks related to intellectual property, regulatory approvals, and competition.

Future Outlook

The company expects its current cash reserves to fund operations through the end of the first quarter of calendar 2025, depending on the level and timing of realizing BayMedica revenues and operating expenses. The company will continue to seek additional funding through equity financings, debt financings, or other capital sources.

Management Comments

• Management has determined that the company's liquidity condition raises substantial doubt about its ability to continue as a going concern.
• Management is focused on advancing drug candidates and manufacturing technologies into and through clinical development.
• Management is pursuing strategic partnership opportunities for INM-755 in epidermolysis bullosa and other itch-related skin conditions.

Industry Context

The company operates in the pharmaceutical and cannabinoid industries, which are characterized by high research and development costs, regulatory hurdles, and competition. The company's focus on rare cannabinoids and novel cannabinoid analogs positions it in a niche market within the broader industry.

Comparison to Industry Standards

• InMed's revenue growth of 40% year-over-year is a positive sign, but it is important to compare this to the growth rates of other companies in the cannabinoid and pharmaceutical sectors.
• The company's net loss of $1.7 million is significant and needs to be compared to the profitability of similar-stage companies in the industry.
• The company's research and development expenses, while decreased year-over-year, are still substantial and should be benchmarked against industry averages for companies with similar pipelines.
• The company's cash position of $5.6 million is relatively low and needs to be compared to the cash reserves of other companies in the sector, especially given the going concern warning.
• The reverse stock split is a common strategy for companies facing delisting, but its effectiveness in maintaining compliance with Nasdaq requirements is not guaranteed.

Legal Proceedings

• BayMedica is involved in a dispute with a licensor regarding a patent license agreement, but no lawsuit has been initiated.

Related Party Transactions

• Legal services were provided to the company by Norton Rose Fulbright Canada LLP, where a director of the company is a partner.

Stakeholder Impact

• Shareholders face the risk of further dilution and potential loss of investment value due to the company's need for additional capital and the potential for delisting.
• Employees may be concerned about the company's financial stability and future prospects.
• Customers of BayMedica may be impacted by any changes in the company's operations or financial condition.
• Suppliers and creditors may be concerned about the company's ability to meet its obligations.

Next Steps

• The company needs to maintain a minimum bid price of $1.00 for ten consecutive trading days to regain compliance with Nasdaq listing rules.
• The company will continue to advance its drug candidates and manufacturing technologies.
• The company will continue to seek additional funding through equity financings, debt financings, or other capital sources.
• The company will continue to evaluate opportunities for potential structured supply arrangements and collaborations for the commercial business.

Key Dates

Keywords

pharmaceuticals, cannabinoids, reverse stock split, Nasdaq, financial results, research and development, BayMedica, capital raise, going concern